Orion Pharmaceuticals Implements Genedata Biologics to Support New Large-Molecule R&D Initiative

Wednesday, September 11, 2019 General News
Email Print This Page Comment bookmark
Font : A-A+

Genedata Biologics to accelerate antibody discovery and streamline R&D operations at Finland's largest biopharma company.

BASEL, Switzerland, September 11, 2019 /PRNewswire-PRWeb/ -- Genedata, the leading provider of enterprise software solutions

for biopharmaceutical R&D, today announced Orion Pharma, a globally operating Finnish pharmaceutical company, has licensed Genedata Biologics® to support their R&D in the areas of oncology, the central nervous system, and other medical indications.

"As part of our strategy to expand our biopharmaceutical R&D operations, we are implementing Genedata as our central workflow backbone to streamline our large-molecule R&D processes," said Tim Holmström, Head of Biologics at Orion Pharma. "Genedata Biologics was the obvious choice because it is a proven, off-the-shelf enterprise platform that can be rapidly deployed across our organization. Also, collaborating with CROs is a key part of our strategy, so we require an open and scalable system able to capture and integrate all data generated by our CRO network. Finally, Genedata's offering of Software-as-a-Service (SaaS) was an additional plus because we wanted a self-maintaining model that provides regular upgrades of new, innovative functionalities."

Genedata Biologics enables Orion scientists to easily capture, process, and interpret all large-molecule R&D data and facilitate the design of antibodies. Further, it integrates all assay and analytics data to enable a comprehensive assessment of all drug candidates. The platform helps eliminate error-prone manual processes by providing a robust, standardized data repository that can be integrated with laboratory instrumentation. All molecule, sample, assay and analytics data, including developability and manufacturability data, are managed within one fully integrated system and are shared between different project teams and sites. The platform facilitates systematic and transparent decision-making to select drug candidates to be progressed through the development pipeline.

"We are very pleased that Orion, an innovative R&D-based pharmaceutical company, has selected Genedata Biologics as their workhorse platform for their biopharma R&D operations. By providing Orion with a backbone that covers their entire discovery pipeline in a single system, we help to increase the efficiency of their R&D processes and speed up decision making," said Dr. Othmar Pfannes, CEO of Genedata. "Our technology, combined with Orion's unique scientific approach, will bring cutting-edge therapeutics to patients faster and help them live better and longer lives."

About Genedata Genedata transforms data into intelligence with innovative software solutions and domain-specific consulting services that automate complex, large-scale experimental processes and enable organizations to maximize the ROI from their R&D. Founded in 1997, Genedata is headquartered in Switzerland and has offices in Germany, the UK, Japan, and the US.

http://www.genedata.com

Follow Us on LinkedIn.

Disclaimer The statements in this press release that relate to future plans, events or performance are forward-looking statements that involve risks and uncertainties, including risks associated with uncertainties related to contract cancellations, developing risks, competitive factors, uncertainties pertaining to customer orders, demand for products and services, development of markets for the Company's products and services. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to release publicly the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

All product and service names mentioned are the trademarks of their respective companies.

 

SOURCE Genedata



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store